DMARDs & Immunosuppressives

Tildrakizumab Promising for Psoriasis in Patients with PsA

December 2, 2019 • By Michele B. Kaufman, PharmD, BCGP

Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA

November 25, 2019 • By Michele B. Kaufman, PharmD, BCGP

Scottish Medicines Consortium Recommends Risankizumab; Plus Real-World Data on Secukinumab

November 4, 2019 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Rituximab for Children with GPA & MPA

October 23, 2019 • By Michele B. Kaufman, PharmD, BCGP

Iguratimod May Hold Promise for Treating Autoimmune Disease

October 22, 2019

Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

October 14, 2019 • By Mary Choy, PharmD, BCGP, FASHP

Abx464 Enters Phase 2 Clinical Trials for RA in Europe

September 30, 2019 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Ixekizumab for Treating Active Ankylosing Spondylitis

September 23, 2019 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Upadacitinib for RA

September 2, 2019 • By Michele B. Kaufman, PharmD, BCGP

Filgotinib Promising for RA

August 26, 2019 • By Michele B. Kaufman, PharmD, BCGP